FIB-4 and APRI for cirrhosis detection in a privately insured national cohort

Shah, 2009, Use of the FIB-4 index for non-invasive evaluation of fibrosis in nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 7, 1104, 10.1016/j.cgh.2009.05.033 McPherson, 2010, Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease, Gut, 59, 1265, 10.1136/gut.2010.216077 Loaeza-del-Castillo, 2008, AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis, Ann Hepatol, 7, 350, 10.1016/S1665-2681(19)31836-8 Sterling, 2006, Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology, 43, 1317, 10.1002/hep.21178 Lackner, 2005, Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C, Hepatology, 41, 1376, 10.1002/hep.20717 Lee, 2021, Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review, Liver Int, 41, 261, 10.1111/liv.14669 Labenz, 2022, Structured early detection of asymptomatic liver cirrhosis: results of the population-based liver screening program SEAL, J Hepatol, 77, 695, 10.1016/j.jhep.2022.04.009 Ginès, 2022, Population screening for liver fibrosis: toward early diagnosis and intervention for chronic liver diseases, Hepatology, 75, 219, 10.1002/hep.32163 Lomonaco, 2021, Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening, Diabetes Care, 44, 399, 10.2337/dc20-1997 Jacqueminet, 2008, Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes, Clin Gastroenterol Hepatol, 6, 828, 10.1016/j.cgh.2008.03.005 Panel, 2021, EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis–2021 update, J Hepatol, 75, 659, 10.1016/j.jhep.2021.05.025 Graupera, 2022, Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population, Clin Gastroenterol Hepatol, 20, 2567, 10.1016/j.cgh.2021.12.034 Rinella, 2023, AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease, Hepatology, 10.1097 Dillon, 2019, Intelligent liver function testing (iLFT): a trial of automated diagnosis and staging of liver disease in primary care, J Hepatol, 71, 699, 10.1016/j.jhep.2019.05.033 Srivastava, 2019, Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease, J Hepatol, 71, 371, 10.1016/j.jhep.2019.03.033 Chalmers, 2020, Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community, Frontline Gastroenterol, 11, 86, 10.1136/flgastro-2019-101177 Graupera, 2022, LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries, BMC public health, 22, 1, 10.1186/s12889-022-13724-6